Key Takeaways Shares of ResMed and Inspire Medical Systems fell after the FDA approved Eli Lilly's weight-loss drug Zepbound ...

The FDA approved Eli Lilly's (LLY) obesity drug for the treatment of sleep apnea, sending rival ResMed (RMD) stock lower ...

The S&P 500 added 0.7% on Monday, Dec. 23, 2024, with tech stocks outperforming as the holiday-shortened week got underway.

Popular weight-loss drugs like Wegovy and Zepbound are boosting the use of healthcare in the U.S., leading to an uptick in ...

A medical vendor with decades of experience making medical-grade head gear has revealed a new strap to make the Apple Vision ...

ResMed has established itself as a key player in the sleep and respiratory care market, with a primary focus on devices for sleep apnea and other respiratory conditions. The company's consistent ...

Sleep apnea can significantly increase health risks, even the risk of death, so doctors strongly recommend people address it. But standard therapy with breathing devices known as CPAPs are not hugely ...

ResMed, Inc. holds a ... accessories for the treatment of sleep-disordered breathing (SDB) and other respiratory disorders. SDB includes obstructive sleep apnea (OSA) and other respiratory ...

Various medical devices are available to help treat sleep apnea. Choosing the right one comes down to the severity of your condition, your personal preferences, and your lifestyle. Sleep apnea is ...

The sleep screening devices market is projected to grow from US$ 9,298 million in 2023 to US$ 17,564.5 million by 2033, at a ...

ResMed's Chief Medical Officer has suggested doctors will prescribe using both drugs and devices such as his company makes together to help sleep apnea suffers. Shares of ResMed (RMD) and Inspire ...